Pressemitteilung BoxID: 340608 (ProBioGen AG)
  • ProBioGen AG
  • Goethestr. 54
  • 13086 Berlin
  • Ansprechpartner
  • Gertraud Unterrainer
  • +49 (30) 924006-0

ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals

(PresseBox) (Berlin, ) ProBioGen AG ("ProBioGen"), a technology and service provider for the development and production of biopharmaceutical drug substances today announced signing a contract with Virdante Biopharmaceuticals, Inc., a USbased biopharmaceutical development company ("Virdante").

ProBioGen will contribute producer cell line development and process engineering for one of Virdante's proprietary therapeutic proteins. Virdante's protein products are unique in that they incorporate the company's proprietary "Sialic Switch" technology that improves the antiinflammatory properties of an antibody for autoimmune and inflammatory diseases. Virdante selected ProBioGen for its expertise in developing royaltyfree pharmaceutical cell lines and robust, economical processes for GMPmanufacturing.

"We are highly impressed by Virdante's products and strategies and their compelling scientific rationale to improve human proteins. We are excited to contribute our knowledge in harnessing the cellular machinery to maximize productivity for this ambitious project", commented Dr. Volker Sandig, Chief Scientific Officer of ProBioGen.

About Virdante

Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. Our products incorporate a proprietary "Sialic Switch" technology to improve the antiinflammatory properties of antibodies. Virdante is located in Cambridge, MA.

ProBioGen AG

ProBioGen is a technology and service provider that supports and adds value to its clients' biopharmaceutical drug development. A proven track record of feeforservicebased projects, from cell line development, over process engineering, up to GMP manufacturing is strengthened by novel expression systems and unique analytical testing services.

In addition to its CHO platform, ProBioGen has developed proprietary AGE1® producer cell lines, for safe and costefficient production of highly active glycoproteins, monoclonal antibodies and virusbased vaccines. ProBioGen employs a broad range of qualified cellbased assays and a services and technologies are embedded in a total quality management system, compliant with international ISO and GMP standards. ProBioGen was founded in 1994 and is located in Berlin, Germany.